© 2016 The Author(s). Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with 68Ga-PSMA ligand Positron emission tomography/computed tomography (PET/CT). However, prospective trials and clinical guidelines for this new technique are still missing. Therefore, we summarized our experience with 68Ga-PSMA ligand PET/CT examinations in patients with primary PC and biochemical recurrence. It focuses on the technical and logistical aspects of 68Ga-PSMA ligand PET/CT examination as well as on the specific background for image reading discussing also potential pitfalls. Further, it includes relevant issues on free-text as well as structured reporting used in daily clinical routine.
Rauscher, I., Maurer, T., Fendler, W. P., Sommer, W. H., Schwaiger, M., & Eiber, M. (2016, June 8). 68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. Cancer Imaging. BioMed Central Ltd. https://doi.org/10.1186/s40644-016-0072-6